<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">38269</article-id><article-id pub-id-type="doi">10.7554/eLife.38269</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Concerted IL-25R and IL-4Rα signaling drive innate type 2 effector immunity for optimal helminth expulsion</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-113048"><name><surname>Smith</surname><given-names>Katherine A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8150-5702</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-113049"><name><surname>Löser</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-113050"><name><surname>Varyani</surname><given-names>Fumi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-113051"><name><surname>Harcus</surname><given-names>Yvonne</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-113052"><name><surname>McSorley</surname><given-names>Henry J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-31684"><name><surname>McKenzie</surname><given-names>Andrew NJ</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-108357"><name><surname>Maizels</surname><given-names>Rick M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3216-1944</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Cardiff Institute of Infection and Immunity</institution>, <institution>Cardiff University</institution>, <addr-line><named-content content-type="city">Cardiff</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation</institution>, <institution>University of Glasgow</institution>, <addr-line><named-content content-type="city">Glasgow</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">MRC Centre for Inflammation Research</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution content-type="dept">Protein and Nucleic Acid Chemistry Division</institution>, <institution>MRC Laboratory of Molecular Biology</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-13704"><name><surname>MacPherson</surname><given-names>Andrew J</given-names></name><role>Reviewing editor</role><aff><institution>University of Bern</institution>, <country>Switzerland</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>SmithK28@Cardiff.ac.uk</email> (KS);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>rick.maizels@glasgow.ac.uk</email> (RM);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>09</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e38269</elocation-id><history><date date-type="received"><day>10</day><month>05</month><year>2018</year></date><date date-type="accepted"><day>21</day><month>09</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Smith et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Smith et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-38269-v1.pdf"/><abstract><p>Interleukin 25 (IL-25) is a major 'alarmin' cytokine, capable of initiating and amplifying the type 2 immune response to helminth parasites. However its role in the later effector phase of clearing chronic infection remains unclear. The helminth <italic>Heligmosomoides polygyrus</italic> establishes long-term infections in susceptible C57BL/6 mice, but is slowly expelled in BALB/c mice from day 14 onwards. We noted that IL-25R (<italic>Il17rb</italic>)-deficient BALB/c mice were unable to expel parasites despite type 2 immune activation comparable to the wild-type. We then established that in C57BL/6 mice, IL-25 adminstered late in infection (days 14-17) drove immunity. Moreover when IL-25 and IL-4 were delivered to <italic>Rag1</italic>-deficient mice, the combination resulted in near complete expulsion of the parasite, even following administration of an anti-CD90 antibody to deplete innate lymphoid cells (ILCs). Hence, effective anti-helminth immunity during chronic infection requires an innate effector cell population that is synergistically activated by the combination of IL-4Rα and IL-25R signaling.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>106122</award-id><principal-award-recipient><name><surname>Maizels</surname><given-names>Rick M</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>90281</award-id><principal-award-recipient><name><surname>Maizels</surname><given-names>Rick M</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>657639</award-id><principal-award-recipient><name><surname>Smith</surname><given-names>Katherine A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal protocols adhered to the guidelines of the UK home office and complied with the Animals (Scientific Procedures) Act 1986. The protocols were approved by the Ethical Review Committees of the University of Edinburgh (UK Home Office Project number 60/4105) and the University of Glasgow (Project number 70/8384).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-38269-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>